Allianz Asset Management Gmb H Innoviva, Inc. Transaction History

Allianz Asset Management Gmb H

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$10.73 - $13.6 $770,414 - $976,480	71,800 Added 178.61%	112,000 $1.26 Million
Q4 2022 Feb 13, 2023	BUY	$11.8 - $13.78 $474,360 - $553,956	40,200 New	40,200 $532,000
Q1 2021 May 13, 2021	SELL	$11.06 - $12.87 $155,946 - $181,467	-14,100 Reduced 51.09%	13,500 $161,000
Q3 2020 Nov 13, 2020	SELL	$10.33 - $14.49 $52,466 - $73,594	-5,079 Reduced 15.54%	27,600 $288,000
Q2 2020 Aug 14, 2020	BUY	$11.49 - $15.26 $375,481 - $498,681	32,679 New	32,679 $457,000
Q1 2018 May 14, 2018	SELL	$13.8 - $16.99 $1.17 Million - $1.44 Million	-84,545 Closed	0 $0
Q4 2017 Feb 13, 2018	SELL	$11.73 - $14.75 $390,808 - $491,425	-33,317 Reduced 28.27%	84,545 $1.2 Million
Q3 2017 Nov 13, 2017	BUY	$12.06 - $14.12 $1.01 Million - $1.18 Million	83,910 Added 247.14%	117,862 $1.66 Million
Q2 2017 Aug 14, 2017	SELL	N/A	-109,319 Reduced 76.3%	33,952 $437,000
Q1 2017 Apr 17, 2019	SELL	N/A	-8,452 Reduced 5.57%	143,271 $1.98 Million
Q4 2016 Apr 17, 2019	SELL	N/A	-4,769 Reduced 3.05%	151,723 $1.62 Million
Q3 2016 Apr 17, 2019	BUY	N/A	156,492	156,492 $1.7 Million

228

78.9M

37.6K

300

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.2B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Allianz Asset Management Gmb H with notifications on news.